Incyte, TG's PI3K Inhibitors Show Safety Advantage In Indolent NHL

Data At ASH Show Strong Efficacy, Favorable Safety For Umbralisib, Parsaclisib

 
• By Alaric DeArment
  
Cancer
Incyte and TG Therapeutics presented Phase II data on their PI3K inhibitors at ASH. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category